News

The company has previously received allowances of broad claims surrounding the use of its Ii-Key hybrid technology platform. Both applications relate to vaccines designed using this platform, which

These product candidates – two GITR agonists and a CTLA-4 antagonist – target cell-surface checkpoint proteins that control immune responses. They are part of Agenus’ recent acquisition of

Soltamox offers an option to patients who may prefer or need a liquid form of tamoxifen. The inclusion of Soltamox on the Medicare Part D Formulary allows broad,

The company said that proceeds from the financing will be used to advance development of its lead product candidate ZS-9, for the treatment of hyperkalemia, through its new

Jetrea is a selective proteolytic enzyme that cleaves fibronectin, laminin and collagen, three major components of the vitreoretinal interface that play a major role in VMA. The Ocriplasmin

The deal will see the companies provide a wider range of drug discovery and translational medicine services, including expanded profiling and molecule testing, especially in the context of

CFFT is the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation. The extension will focus on moving the company’s lead compounds toward a development candidate

The company said that the licence agreement is with the same partner that will be supplying the women’s health product that is being prepared for launch in the

The company has announced this voluntary recall to the user level following the discovery of four leaking premix bags during an investigation conducted in response to a product